CRP and metabolic syndrome: To date, accumulating evidence indicates that NAFLD, especially its necro-inflammatory and progressive form (NASH), may exacerbate insulin resistance, predisposes to atherogenic dyslipidemia and releases a myriad of pro-inflammatory, pro-coagulant, pro-oxidant and pro-fibrogenic mediators (e.g., C-reactive protein, IL-6, fibrinogen, plasminogen activator inhibitor-1, transforming growth factor-β) that may play important roles in the pathophysiology of psoriasis [5,9,31,35].